糖心vlog

[Skip to Navigation]
Sign In

October 2024 - April 2015

Decade

Year

Issue

April 2022, Vol 8, No. 4, Pages 506-651

Original Investigation

Characteristics of Clinical Trials Evaluating Biosimilars in the Treatment of Cancer: A Systematic Review and Meta-analysis

Abstract Full Text
free access
JAMA Oncol. 2022;8(4):537-545. doi:10.1001/jamaoncol.2021.7230

This systematic review and meta-analysis examines the design of cancer biosimilar efficacy studies compared with the reference drug pivotal trials and provides summary risk ratio estimates for each cancer type drug subgroup.

Efficacy and Safety of Autologous Dendritic Cell鈥揃ased Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2022;8(4):546-552. doi:10.1001/jamaoncol.2021.7298

This randomized clinical trial evaluates the efficacy and safety of DCVAC/PCa plus chemotherapy followed by DCVAC/PCa maintenance treatment in patients with metastatic castration-resistant prostate cancer.

Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy: A Phase 3 Randomized Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2022;8(4):553-561. doi:10.1001/jamaoncol.2021.7366

This randomized clinical trial investigates the efficacy and safety of capecitabine maintenance therapy for patients with newly diagnosed metastatic nasopharyngeal carcinoma who had achieved disease control after induction chemotherapy.

Palliative Radiation for Advanced Central Lung Tumors With Intentional Avoidance of the Esophagus (PROACTIVE): A Phase 3 Randomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. 2022;8(4):562-568. doi:10.1001/jamaoncol.2021.7664

This randomized clinical trial compares the use of esophageal-sparing intensity-modulated radiotherapy with standard palliative radiotherapy in patients with incurable non鈥搒mall cell lung cancer.

Effect of a Symptom Monitoring Intervention for Patients Hospitalized With Advanced Cancer: A Randomized Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2022;8(4):571-578. doi:10.1001/jamaoncol.2021.7643

This nonblinded randomized clinical trial compares the effects of a symptom monitoring intervention vs usual care on symptom burden and health care use among hospitalized adult patients with advanced cancer.

Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor鈥揚ositive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation: A Post Hoc Analysis of a Randomized Clinical Trial

Abstract Full Text
free access has audio
JAMA Oncol. 2022;8(4):579-586. doi:10.1001/jamaoncol.2021.7656

This post hoc analysis of a randomized clinical trial examines the recurrence and survival rates in women with breast cancer of differing racial and sociodemographic groups.

Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis

Abstract Full Text
free access
JAMA Oncol. 2022;8(4):587-596. doi:10.1001/jamaoncol.2021.6204

This decision analytical study uses microsimulation models from the Cancer Intervention and Surveillance Modeling Network to estimate the benefits and harms associated with breast cancer screening strategies using mammography and magnetic resonance imaging at various start ages for women with ATM, CHEK2, and PALB2 pathogenic variants.

Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer

Abstract Full Text
free access
JAMA Oncol. 2022;8(4):597-606. doi:10.1001/jamaoncol.2021.8049

This economic evaluation examines the cost-effectiveness of pertuzumab, trastuzumab, and chemotherapy vs trastuzumab and chemotherapy for patients with metastatic breast cancer.

Brief Report

Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue

Abstract Full Text
free access
JAMA Oncol. 2022;8(4):607-610. doi:10.1001/jamaoncol.2021.7239

This study determines the suitability of the current standard ERBB2 immunohistochemistry assays to select patients with low ERBB2 positivity for treatment with trastuzumab deruxtecan.

SARS-CoV-2 Antibody Response to 2 or 3 Doses of the BNT162b2 Vaccine in Patients Treated With Anticancer Agents

Abstract Full Text
free access has active quiz
JAMA Oncol. 2022;8(4):612-617. doi:10.1001/jamaoncol.2021.7777

This cohort study examines the use of a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer.

Research Letter

Development of an Open Database of Genes Included in Hereditary Cancer Genetic Testing Panels Available From Major Sources in the US

Abstract Full Text
open access
JAMA Oncol. 2022;8(4):637-639. doi:10.1001/jamaoncol.2021.7639

This quality improvement study describes the development of an open database of genes included in hereditary cancer genetic testing panels from major US providers and also discusses publicly available variant data for those genes.

Association of Human Papillomavirus Vaccination With the Incidence of Squamous Cell Carcinomas of the Anus in the US

Abstract Full Text
free access
JAMA Oncol. 2022;8(4):639-641. doi:10.1001/jamaoncol.2021.7652

This cross-sectional study uses data from the US Cancer Statistics database to examine the association of human papillomavirus (HPV) vaccination with incidence of squamous cell carcinomas of the anus in a vaccine-eligible US cohort.

Special Communication

Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease

Abstract Full Text
has active quiz
JAMA Oncol. 2022;8(4):618-628. doi:10.1001/jamaoncol.2021.7148

The findings of this systematic review were reviewed to develop recommendations for the care of adults with extramammary Paget disease.

Review

Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast Cancer: A Review

Abstract Full Text
has active quiz
JAMA Oncol. 2022;8(4):629-635. doi:10.1001/jamaoncol.2021.6597

This narrative review examines the rate of patients with Erb-B2 receptor tyrosine kinase 2-positive metastatic breast cancer experiencing long-lasting responses to cancer treatment.

Viewpoint

Reexamination of Patient Autonomy and Prior Therapies in Oncology Clinical Trial Eligibility Criteria

Abstract Full Text
JAMA Oncol. 2022;8(4):513-514. doi:10.1001/jamaoncol.2021.7249

This Viewpoint describes new draft guidance from the US Food and Drug Administration encouraging inclusion of all patients with incurable cancers in cancer clinical trials.

Achieving Equity in Lung Cancer Screening for Black Individuals Requires Innovation to Move Beyond 鈥淓qual鈥 Guidelines

Abstract Full Text
JAMA Oncol. 2022;8(4):514-515. doi:10.1001/jamaoncol.2021.7252

This Viewpoint discusses the need for innovation in lung cancer screening for Black individuals.

Editorial

Cancer Biosimilars鈥擜 Regulatory Success So Far, but Value Still to Be Determined

Abstract Full Text
JAMA Oncol. 2022;8(4):520-521. doi:10.1001/jamaoncol.2021.6979

Active Cellular Immunotherapy in the Desert of Advanced Prostate Cancer

Abstract Full Text
JAMA Oncol. 2022;8(4):522-523. doi:10.1001/jamaoncol.2021.7282

Maintenance Capecitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma鈥擬agic Bullet or Pandora鈥檚 Box?

Abstract Full Text
JAMA Oncol. 2022;8(4):524-525. doi:10.1001/jamaoncol.2021.7365
Invited Commentary

Tumor Coverage vs Healthy Tissue Sparing鈥擶hat Is the Balance When Palliation Is the Goal?

Abstract Full Text
JAMA Oncol. 2022;8(4):569-570. doi:10.1001/jamaoncol.2021.7604

ERBB2-Low Breast Cancer鈥擨s It a Fact or Fiction, and Do We Have the Right Assay?

Abstract Full Text
JAMA Oncol. 2022;8(4):610-611. doi:10.1001/jamaoncol.2021.7082
Cancer Care Chronicles

Patient Harassment of Medical Trainees: Reflections for a More Inclusive Future

Abstract Full Text
JAMA Oncol. 2022;8(4):516-517. doi:10.1001/jamaoncol.2021.7224

This essay describes examples of harassment and bias experienced by medical trainees from their patients.

Overcoming Our Red Dots and Confronting Racism From Patients

Abstract Full Text
JAMA Oncol. 2022;8(4):518-519. doi:10.1001/jamaoncol.2021.7227

This essay describes the author鈥檚 experiences facing racism from patients and recommendations for ways to create more inclusive environments for physicians who experience racism.

Poetry and Oncology

Home

Abstract Full Text
JAMA Oncol. 2022;8(4):651. doi:10.1001/jamaoncol.2021.7246
Comment & Response

Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer

Abstract Full Text
JAMA Oncol. 2022;8(4):641-642. doi:10.1001/jamaoncol.2021.7784

Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer

Abstract Full Text
JAMA Oncol. 2022;8(4):642. doi:10.1001/jamaoncol.2021.7787

Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer鈥擱eply

Abstract Full Text
JAMA Oncol. 2022;8(4):642-643. doi:10.1001/jamaoncol.2021.7790

PSMA PET in Prostate Cancer鈥擜 Biomarker or a Surrogate End Point?

Abstract Full Text
JAMA Oncol. 2022;8(4):643-644. doi:10.1001/jamaoncol.2021.7991

PSMA PET in Prostate Cancer鈥擜 Biomarker or a Surrogate End Point?鈥擱eply

Abstract Full Text
JAMA Oncol. 2022;8(4):644-645. doi:10.1001/jamaoncol.2021.7994

Association of Residual Cancer Burden After Neoadjuvant Therapy and Event-Free Survival in Breast Cancer

Abstract Full Text
JAMA Oncol. 2022;8(4):645. doi:10.1001/jamaoncol.2021.7997

Association of Residual Cancer Burden After Neoadjuvant Therapy and Event-Free Survival in Breast Cancer鈥擱eply

Abstract Full Text
JAMA Oncol. 2022;8(4):645-646. doi:10.1001/jamaoncol.2021.8000

Interpretation of the Efficacy of Multidisciplinary Geriatric Assessment Intervention on Chemotherapy-Related Toxic Effects in Older Adults With Cancer

Abstract Full Text
JAMA Oncol. 2022;8(4):646-647. doi:10.1001/jamaoncol.2021.8061

Interpretation of the Efficacy of Multidisciplinary Geriatric Assessment Intervention on Chemotherapy-Related Toxic Effects in Older Adults With Cancer

Abstract Full Text
JAMA Oncol. 2022;8(4):647. doi:10.1001/jamaoncol.2021.8064

Interpretation of the Efficacy of Multidisciplinary Geriatric Assessment Intervention on Chemotherapy-Related Toxic Effects in Older Adults With Cancer鈥擱eply

Abstract Full Text
JAMA Oncol. 2022;8(4):647-648. doi:10.1001/jamaoncol.2021.8067
Correction

Errors in Abstract, Text, and Tables

Abstract Full Text
free access
JAMA Oncol. 2022;8(4):648. doi:10.1001/jamaoncol.2022.0019
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2022;8(4):506. doi:10.1001/jamaoncol.2021.5491
×